Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 aggregate principal amount of its 3.72% Senior Notes, Series 2017A, due November 1, 2027 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13. The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 75,000,000 aggregate principal amount of its 3.72% Senior Notes, Series 2017A2005-B, due November 1October 30, 2027 2020 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”). As used herein, such the term “Notes” shall mean all notes originally delivered pursuant to include this Agreement and any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement. The Notes shall be substantially in the form set out in Exhibit 1, 1 with such changes therefrom, if any, as may be approved by each Purchaser the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of its $15,000,000 40,000,000 aggregate principal amount of its 3.724.04% Senior Notes, Series 2017A2019, due November 1September 12, 2027 2049 (as amended, restated or otherwise modified from time to time pursuant to Section 17, are referred to as the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 125,000,000 aggregate principal amount of its 3.722.38% Senior Guaranteed Notes, Series 2017AC, due November 1August 17, 2027 2030 (the “Notes,” such term to include any such notes as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”), such term to include 17 and including any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1, with such changes therefrom, if any, as may be approved by each Purchaser the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references A. References to a “Schedule” or an “Exhibit” are, are references to a Schedule attached to this Agreement unless otherwise specified, . References to a Schedule or an Exhibit attached “Section” are references to a Section of this AgreementAgreement unless otherwise specified.

Authorization of Notes. The Company Issuer will authorize the issue and sale of $15,000,000 41,050,763 in aggregate principal amount of its 3.726.07% Senior ESOP Guaranteed Notes due December 31, 2009 (the "Notes, Series 2017A, due November 1, 2027 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”)", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser you, the Issuer and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 50,000,000 aggregate principal amount of its 3.724.42% Senior Notes, Series 2017A2014, due November 1October 15, 2027 2044 (each as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 30,000,000 aggregate principal amount of its 3.723.70% Senior Notes, Series 2017A2016, due November August 1, 2027 2026 (each as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of its $15,000,000 40,000,000 aggregate principal amount of its 3.723.78% Senior Notes, Series 2017A2020, due November 1September 15, 2027 2040 (as amended, restated or otherwise modified from time to time pursuant to Section 17, are referred to as the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Issuer and the Company will authorize have authorized the issue and sale of $15,000,000 65,000,000 aggregate principal amount of its 3.72the Issuer’s 4.07% Senior Guaranteed Notes, Series 2017Adue August 15, due November 1, 2027 2025 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”), such term to include any such notes Notes issued in substitution therefor pursuant to Section 1314 of this Agreement). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser such Purchasers of such Notes, the Company, and the CompanyIssuer. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 100,000,000 aggregate principal amount of its 3.72% Floating Rate Senior NotesSecured Notes due October 12, Series 2017A, due November 1, 2027 2012 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”). As used herein, such the term “Notes” shall mean all notes originally delivered pursuant to include this Agreement and any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement. The Notes shall be substantially in the form set out in Exhibit 1, 1 with such changes therefrom, if any, as may be approved by each Purchaser the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 27,500,000 aggregate principal amount of its 3.723.78% Senior Notes, Series 2017A2020A, due November 1September 15, 2027 2040 (each, as amended, restated or otherwise modified from time to time pursuant to Section 17, are collectively referred to as the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 30,000,000 aggregate principal amount of its 3.723.43% Senior Notes, Series 2017A2019, due November 1December 18, 2027 2029 (each as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 100,000,000 aggregate principal amount of its 3.726.28% Senior NotesGuaranteed Notes due April 7, Series 2017A, due November 1, 2027 2020 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, . Due and punctual payment of the Guaranteed Obligations (as may defined herein) will be approved unconditionally guaranteed by each Purchaser and the CompanyGuarantors (the “ Subsidiary Guaranty”) as set forth in this Agreement. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of Fifty Million Dollars ($15,000,000 50,000,000) aggregate principal amount of its 3.726.77% Senior Notes due May 8, 2010 (the "Notes, Series 2017A, due November 1, 2027 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”)", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of Seventy-Five Million Dollars ($15,000,000 75,000,000) aggregate principal amount of its 3.726.50% Senior NotesNotes due December 8, Series 2017A, due November 1, 2027 2008 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”)"NOTES", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of Seventy-Five Million Dollars ($15,000,000 75,000,000) aggregate principal amount of its 3.726.50% Senior Notes due December 8, 2008 (the "Notes, Series 2017A, due November 1, 2027 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”)", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $15,000,000 40,000,000 aggregate principal amount of its 3.726.85% Senior Guaranteed Notes due December 23, 2004 (the "Notes, Series 2017A, due November 1, 2027 (as amended, restated or otherwise modified from time to time pursuant to Section 17, the “Notes”)", such term to include any such notes issued in substitution therefor pursuant to Section 13SECTION 11 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, EXHIBIT 1 with such changes therefrom, if any, as may be approved by each Purchaser you and the CompanyCompany in accordance with SECTION 15.1. Certain capitalized and other terms used in this Agreement are defined in Schedule SCHEDULE B; and references to a “Schedule” "SCHEDULE" or an “Exhibit” "EXHIBIT" are, unless otherwise specified, to a Schedule SCHEDULE or an Exhibit EXHIBIT attached to this Agreement.